Tumor neoantigen is a new direction of tumor treatment, and it is a truly personalized treatment plan. During the growth of cancer cells, a series of DNA-specific mutations are often accompanied by a series of DNA-specific mutations, stimulating cancer cells to develop drug resistance or rapid growth, and this specific mutation is different in tumor cells of different patients, making traditional tumor drugs less effective. Tumor neoantigens are protein or polypeptide fragments produced by tumor cell-specific mutations, which have individual differences and immune tolerance, and are ideal targets for drugs and treatments. Tumor neoantigen drugs represent a new direction for tumor treatment, and the application of relevant drugs and the implicit approval of clinical trials mark that personalized precision therapy has entered the clinical stage.

Our Services

Due to the unclear application declaration rules for neoantigen peptides and the need for compliance assurance, based on years of experience in peptide synthesis, Alfa Oncology has launched a new neoantigen peptide service, including neoantigen peptide IND declaration services, to meet the needs of personalized treatment in an all-round way research needs to facilitate the IND declaration of anti-tumor neoantigen drugs.

Alfa Oncology has launched a special neoantigen IND declaration service. Through continuous research and accumulation, it will gradually realize the transformation of cancer into a chronic disease and serve the people with more efficient cancer treatment drugs.

Learn more：new antigenic peptide ind service